Side Effects & Safety Per REDEFINE 1 and the Lau (2021) phase 2 program, trial-reported adverse events include: Nausea -- most common (25-40%)
The FDA warns that both CJC-1295 and ipamorelin are risky for immunogenicity, potentially causing life-threatening outcomes such as anaphylaxis.25 26 Cardiovascular concerns: Specifically concerning CJC-1295, the FDA warns of the risk of increased heart rate and systemic vasodilatory reaction, including flushing, warmth, and transient hypotension.25 27 Cancer: With their ability to increase the rate of cellular replication, growth hormone secretagogues in general are unsafe for cancer survivors and people with an active cancer diagnosis.28 Secretagogue use may elevate their risk for recurrence or worsen their prognosis
Use our vendor guide to identify sources that provide batch-specific third-party testing
High-purity, properly lyophilised peptides: Reconstitute more cleanly Maintain structure more effectively Produce more consistent outcomes At DL Peptides, all compounds are supplied in lyophilised form and batch-tested for purity and consistency
Gut issues IBS, leaky gut, NSAID-related GI damage, and chronic intestinal inflammation
.webp)
